In:
Acta Haematologica, S. Karger AG, Vol. 143, No. 3 ( 2020), p. 250-259
Abstract:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Danaparoid sodium and synthetic protease inhibitors (SPIs) have been approved for the treatment of disseminated intravascular coagulation (DIC) in Japan. 〈 b 〉 〈 i 〉 Objectives: 〈 /i 〉 〈 /b 〉 To compare the clinical results of the treatment of DIC with danaparoid or SPIs. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 We retrospectively examined 188 patients with hematological malignancy-related DIC. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 DIC resolution rate in the danaparoid group was higher than that in the SPIs group (61.5 vs. 42.6%; 〈 i 〉 p 〈 /i 〉 = 0.031) on day 7. Multivariate analysis identified the response to chemotherapy as independent predictive factor for DIC resolution on day 7 (odds ratio, OR, 2.28; 95% confidence interval, CI, 1.21–4.31; 〈 i 〉 p 〈 /i 〉 = 0.011). While there was no significant difference in the DIC resolution rate on day 14 (75.0 vs. 62.4%; 〈 i 〉 p 〈 /i 〉 = 0.117), in a subgroup analysis of patients who did not show an improvement in the underlying disease, the danaparoid group showed a significantly better DIC resolution rate (OR 3.89; 95% CI 1.15–13.2; 〈 i 〉 p 〈 /i 〉 = 0.030). There was no difference in the rate of cumulative mortality from bleeding within 28 days between the 2 groups (6.6 vs. 3.3%; 〈 i 〉 p 〈 /i 〉 = 0.278). 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 Danaparoid may be associated with more frequent resolution of DIC in patients with refractory underlying disease.
Type of Medium:
Online Resource
ISSN:
0001-5792
,
1421-9662
Language:
English
Publisher:
S. Karger AG
Publication Date:
2020
detail.hit.zdb_id:
1481888-7
detail.hit.zdb_id:
80008-9